Abstral is a rapidly disintegrating sublingual tablet for management of breakthrough cancer pain  in patients already being treated with opioids. The product contains the pain-relieving substance fentanyl. Abstral allows doses to be cus- tomized according to individual requirements, which is essential for achieving optimal pain relief.

  • The product was initially approved for sales in Europe in 2008. Approval and launch in other major territories has followed, and Abstral is currently available in key markets such as US, Japan, Canada and EU. Globally, the market for Abstral has continued to grow rapidly over the years, and in Europe Abstral is the market leader among all fast-acting fentanyl-based products.
Product Abstral 
Indication Breakthrough cancer pain

Sentynl Therapeutic1, Kyowa Kirin

 Commercial rights  US, Worldwide ex US

1 Sentynl Therapeutics is a fully owned subsidiary of Zydus Cadila